INAB — Stock Film
STOCK FILMSCENE 1/11INAB · $1.19
Stock Expert AI presents
INAB
IN8bio, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
IN8bio, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 18 employees. Now — the numbers.

on the stock market since 2021
18 employees
$11.4M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $2.8M
At this pace, that money lasts about 1.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
46 buy22 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
21
very weak

Clearly below the class average.

FINANCIAL STRENGTH
62
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
68
strong

Clearly above the class average — a step short of the very top.

GROWTH
53
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
22
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 46 buys and 22 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $4.00236% above today’s price.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $19.4M against $0 in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, INAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: INAB is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film